Get the Stockscreener App
12.15
4.56%
-0.58
After Hours:
12.21
0.06
+0.49%
Novocure Ltd stock is traded at $12.15, with a volume of 769.89K.
It is down -4.56% in the last 24 hours and up +7.14% over the past month.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
See More
Previous Close:
$12.73
Open:
$12.72
24h Volume:
769.89K
Relative Volume:
0.49
Market Cap:
$1.36B
Revenue:
$577.74M
Net Income/Loss:
$-149.78M
P/E Ratio:
-8.6786
EPS:
-1.4
Net Cash Flow:
$-78.21M
1W Performance:
-1.06%
1M Performance:
+7.14%
6M Performance:
-41.08%
1Y Performance:
-29.89%
1-Day Range:
$12.15
$12.76
1-Week Range:
$11.98
$13.67
52-Week Range:
$10.87
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
12.15 | 1.37B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
133.73 | 225.15B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.71 | 155.92B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
383.34 | 146.41B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
94.03 | 118.42B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
77.57 | 45.96B | 5.69B | 1.41B | 577.90M | 6.95 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-04-23 | Initiated | SVB Securities | Outperform |
| Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
| Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
| May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
| May-16-22 | Initiated | H.C. Wainwright | Buy |
| Feb-08-22 | Initiated | Loop Capital | Buy |
| Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
| Jan-25-21 | Reiterated | Piper Sandler | Overweight |
| Sep-23-20 | Initiated | Northland Capital | Outperform |
| Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-17-20 | Downgrade | Truist | Buy → Hold |
| Jun-01-20 | Resumed | Oppenheimer | Perform |
| May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
| Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-16-18 | Initiated | Evercore ISI | Outperform |
| Apr-18-18 | Reiterated | Mizuho | Buy |
| Feb-23-18 | Reiterated | Mizuho | Buy |
| May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jul-29-16 | Reiterated | Wedbush | Outperform |
| Jan-19-16 | Initiated | Barclays | Underweight |
| Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
Teza Capital Management LLC Cuts Holdings in NovoCure Limited $NVCR - MarketBeat
Cinctive Capital Management LP Lowers Stake in NovoCure Limited $NVCR - MarketBeat
Cubist Systematic Strategies LLC Sells 83,600 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Limited $NVCR Shares Sold by Hsbc Holdings PLC - MarketBeat
Graham Capital Management L.P. Grows Stock Holdings in NovoCure Limited $NVCR - MarketBeat
Novocure at Morgan Stanley Healthcare Conference: Expanding Cancer Treatment Horizons - Investing.com
NovoCure (NASDAQ:NVCR) Shares Gap Up After Insider Buying Activity - MarketBeat
Ashley Cordova Acquires 81,550 Shares of NovoCure (NASDAQ:NVCR) Stock - MarketBeat
NovoCure (NVCR): Evaluating Valuation After FDA Approval of Optune Lua and Shifts in Investor Positioning - simplywall.st
70,795 Shares in NovoCure Limited $NVCR Purchased by American Century Companies Inc. - MarketBeat
Is NovoCure Limited a turnaround storyMarket Activity Report & Community Trade Idea Sharing Platform - Lancaster City Council
Novocure at H.C. Wainwright: Strategic Growth in Cancer Treatment - Investing.com
What earnings revisions data tells us about NovoCure Limited2025 Trading Recap & Reliable Breakout Stock Forecasts - Newser
Will NovoCure Limited see short term momentumJuly 2025 Highlights & Real-Time Market Sentiment Alerts - Newser
NovoCure Limited $NVCR Shares Sold by Panagora Asset Management Inc. - MarketBeat
What to expect from NovoCure Limited in the next 30 daysWeekly Trend Report & Safe Capital Growth Plans - Newser
Hedge Fund and Insider Trading News: Ken Griffin, Steve Cohen, Anthony Scaramucci, Bill Ackman, Marshall Wace, Point72 Asset Management, Third Point, Brevan Howard, Audioeye Inc (AEYE), NovoCure Ltd (NVCR), and More - Insider Monkey
Top chart patterns to watch in NovoCure LimitedMarket Sentiment Report & AI Forecast for Swing Trade Picks - Newser
NovoCure Limited Stock (NVCR) Opinions on FDA Approval of Optune Lua Device - Quiver Quantitative
Novocure CEO Cordova buys shares worth $996k By Investing.com - Investing.com South Africa
Novocure CEO Cordova buys shares worth $996k - Investing.com India
How to monitor NovoCure Limited with trend dashboards2025 Institutional Moves & Weekly High Potential Alerts - Newser
Novocure announces coverage for Tumor Treating Fields therapy in Spain - MSN
Will NovoCure Limited continue its uptrend2025 Fundamental Recap & Daily Stock Momentum Reports - Newser
NovoCure Limited $NVCR Shares Purchased by Palo Alto Investors LP - MarketBeat
Can NovoCure Limited continue delivering strong returnsJuly 2025 Rallies & Reliable Entry Point Trade Alerts - خودرو بانک
Is NovoCure Limited stock undervalued right nowPortfolio Performance Report & Capital Efficiency Focused Ideas - خودرو بانک
Loss Report: Can NovoCure Limited deliver consistent dividendsShare Buyback & Expert Verified Stock Movement Alerts - خودرو بانک
What machine learning models say about NovoCure Limited2025 Market Outlook & Real-Time Buy Zone Alerts - Newser
How to build a dashboard for NovoCure Limited stockRate Hike & Daily Stock Trend Reports - Newser
Northern Trust Corp Has $22.02 Million Stock Holdings in NovoCure Limited $NVCR - MarketBeat
Novocure at Wells Fargo Conference: Expanding Cancer Treatment Horizons - Investing.com
Is NovoCure Limited exposed to currency risks2025 Market WrapUp & Weekly Top Gainers Trade List - خودرو بانک
American Century Companies Inc. Invests $1.26 Million in NovoCure Limited $NVCR - Defense World
Strategies to average down on NovoCure LimitedJuly 2025 Outlook & Technical Pattern Based Buy Signals - Newser
Does NovoCure Limited show high probability of reboundEarnings Growth Summary & Consistent Return Strategy Ideas - Newser
Can NovoCure Limited recover in the next quarterTrend Reversal & Verified Technical Signals - Newser
What the charts say about NovoCure Limited today2025 AllTime Highs & Low Drawdown Investment Ideas - Newser
Understanding NovoCure Limited’s price movementWeekly Stock Report & AI Enhanced Trade Execution Alerts - Newser
Is NovoCure Limited a top pick in the sectorJuly 2025 Summary & Daily Chart Pattern Signals - خودرو بانک
Invesco Ltd. Lowers Stake in NovoCure Limited $NVCR - Defense World
NovoCure (NVCR) Is Up 5.4% After Spain Reimburses TTFields Therapy—Has The Bull Case Changed? - Yahoo Finance
Can NovoCure Limited generate free cash flowJuly 2025 Reactions & Community Driven Trade Alerts - خودرو بانک
Is NovoCure Limited stock entering bullish territoryGap Up & Verified Entry Point Signals - Newser
How to forecast NovoCure Limited trends using time series2025 Market WrapUp & Stock Timing and Entry Methods - Newser
NovoCure Limited stock momentum explainedDip Buying & Reliable Entry Point Alerts - Newser
Identifying reversal signals in NovoCure LimitedTrade Volume Summary & Long-Term Growth Portfolio Plans - Newser
Price momentum metrics for NovoCure Limited explainedGap Down & Detailed Earnings Play Alerts - Newser
RSI Suggests Rebound May Be Near in NovoCure Limited getLinesFromResByArray error: size == 0 - 더경남뉴스
Nationwide Spanish Reimbursement for TTFields Could Be a Game Changer for NovoCure (NVCR) - simplywall.st
NovoCure Limited stock chart pattern explainedQuarterly Profit Report & Long-Term Investment Growth Plans - Newser
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
1.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):